MaxCyte (MXCT) Q3 2026: Revenue Surges 49% as Akron BioProducts Deal Reshapes the Company

MaxCyte reported third-quarter 2026 revenue of $10.15 million, up 48.7% from a year earlier and well ahead of the $7.47 million consensus estimate, a 35.91% beat. On the bottom line, the company posted a GAAP loss of $0.05 per share against an estimate of negative $0.08, a 40% beat. Gross margin improved to 83% from 77% a year ago, reflecting the richer mix of high-margin license and royalty revenue in the period.

The sharpest acceleration came from the Strategic Platform License program. SPL milestones grew 295% year over year and SPL royalties jumped 486%, together lifting total SPL-related revenue to $2.00 million from $400,000 a year earlier. Instrument sales roughly doubled as well, rising 102% to $2.78 million, while processing assemblies and consumables grew 20% to $3.09 million. The year-ago quarter also included a $3.06 million restructuring charge that did not recur, helping the net loss narrow meaningfully on a year-over-year basis.

The bigger story is what management announced alongside the earnings report. MaxCyte, which carried a market cap of roughly $134 million at the time of the announcement, agreed to acquire Akron BioProducts for $151.8 million in mixed consideration. CEO Maher Masoud said the deal would "nearly double our revenue base and accelerate our path to profitability" by expanding MaxCyte's presence across both viral and non-viral cell therapy development and manufacturing. Akron is expected to contribute approximately $28 million in revenue and $7 to $8 million of EBITDA in 2026, and the transaction is expected to close before year-end.

On a standalone basis, MaxCyte raised its full-year 2026 revenue guidance to at least $34.5 million, comprising roughly $28 million in core revenue and at least $6.5 million in SPL program-related revenue. If the Akron deal closes as planned, the combined company's year-end 2026 cash, equivalents, and investments are expected to land in a range of $40 to $45 million, reflecting roughly $105 million in cash paid plus deal expenses and $22 million drawn under a new MidCap Financial credit facility of up to $75 million.

Looking further out, management pointed to two SPL partner pivotal trials that could yield regulatory approvals as early as next year, and said the combined company with Akron would have more than 100 clinical-stage programs. Combined cash burn is projected to fall from approximately $17 million in 2026 to under $10 million in 2027, with management expressing confidence the company can reach profitability without fully drawing on its credit facility. Key risks include the possibility that the acquisition does not close on schedule, integration execution, new debt obligations, and roughly 20.6 million shares being issued as part of the deal consideration.